AstraZeneca Plots Crucial IDO Phase III Combo Trial With Incyte Post author:Sam Post published:October 30, 2017 Post category:BioPharma Astra and Incyte are pushing forward on the development of immunotherapy combination treatments. Source: BioSpace You Might Also Like Gilead HCV Woes Continue and Investors are Spooked October 26, 2017 NewLink Genetics Stock Plunges After Genentech Bails on $1 Billion+ IDO Deal June 7, 2017 Valeant to Shave an Additional $200M From Its Mountain of Debt January 25, 2018